4D Lifetec's CE IVD certified diagnostic cancer assays

Paper News 1 small

4D Lifetec AG is the pioneering company in non-invasive, immuno-oncological blood test cancer diagnostics. 4D Lifetest™ Lung Dx is our flagship product which we sell with an initial focus on lung cancer diagnostic.


4D Lifetest™ has several possibilities to expand it’s market activities, become a key element in the diagnostic cascade for other major cancer types and support other liquid biopsy methods by adding high early detection sensitivity. Additional applications (4D Lifetest™ Breast, 4D Lifetest™ Prostate, 4D Lifetest™ Colon) are already CE IVD certified.


4D Lifetest™ Lung Dx

Lungenkrebs Diagnostics

Lung cancer patients still have the highest mortality rate of all cancer patients (79% over 5 years) because of a lack of reliable diagnostic biomarkers for early detection. 96% of benign patients undergo unnecessary, highly invasive exclusion testing's.


4D Lifetest™ Lung Dx is a non-invasive, immuno-oncological blood test and verifies lung cancer diagnosis at the earliest stage of the malignancy from patients blood. This unique medical information is required to separate lung cancer patients from healthy or benign individuals during primary diagnosis and direct them in the shortest time towards effective treatment. Additionally, very invasive, burdening and repetitive diagnostic cycles for the surveillance of benign patients can be massively reduced.


4D Lifetest™ Lung Dx is currently launched in the European market starting with a central diagnostic lab (CLIA) in Basel. Primarily the test is targeting the needs of oncology and pulmonary departments of leading hospital centers and key opinion leaders (KOL).



Proven technology ready to market:


  • Novel transformational biomarker DDS (DNA Damage Sensitivity) for the quantification of DNA Fragmentation in tumor and blood cells
  • Proprietary, easy to use workflow and instruments
  • 4 D Lifetest™ is fully proprietary and patent protected in US, Europe and China and filed in other countries worldwide
  • Proven clinical evidence with four publications and more than 200 retrospective and prospective patients from CH, EU and US
  • Unique early stage sensitivity of 90
  • Certified for the European Market (CE IVD Mark CH 202104 0031)



For any further information or for an individual offer, please use our inquiry form or contact us by phone +41 79 434 10 49.